Biotech Values

[DonShimoda]

"If a company ran few trials for one indication and kept going based on consistently good results in that narrow path, the bias is much, much smaller. "

Not necessarily. A post by Dew from a few years back found that "81% of phase III studies have lower response rates than preceding phase II studies" even though the P2 and P3 studies used identical chemotherapeutic regimens.